Essais liés9clinical trials
VilleEdegemlocalisation
PaysBelgiumlocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT07405671

Ouvrir le site du centre

Essais cliniques associés

9
MoléculeIndication / populationPhaseNCTTitreStatut
Survodutide Maladie rénale chronique Phase 3 NCT06077864 A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) COMPLETED
Adagrasib Cancer Phase 2/3 NCT04613596 Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 RECRUITING
Rituximab SEP Phase 3 NCT00004179 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma COMPLETED
flecainide Maladie coronarienne Phase 4 NCT07405671 ReCAST AF — Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation RECRUITING
ZL-1310 Cancer Phase 3 NCT07218146 A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) RECRUITING
Vicadrostat Hypertension Phase 3 NCT07064473 EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease RECRUITING
Pozelimab + Cemdisiran Myasthénie Phase 3 NCT05070858 NIMBLE — A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis ACTIVE_NOT_RECRUITING
Efgartigimod IV or Efgartigimod PH20 SC Myasthénie Phase 2/3 NCT05374590 ADAPT Jr + — Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis ENROLLING_BY_INVITATION
BIBX 1382 Cancer Phase 1 NCT00003980 BIBX 1382 in Treating Patients With Solid Tumors SUSPENDED